1. Sateia MJ. International classification of sleep disorders. Chest 2014;146:1387-1394.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). Washington DC: American Psychiatric Pub; 2013.
4. Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, et al. European guideline for the diagnosis and treatment of insomnia. J Sleep Res 2017;26:675-700.
5. Chung S, Park B, Yi K, Lee J. Pattern of hypnotic drug prescription in South Korea: health insurance review and assessment service-national sample. Sleep Med Res 2013;4:51-55.
8. In: Huang X, Lin J, Demner-Fushman D. Evaluation of PICO as a knowledge representation for clinical questions. editors. AMIA annual symposium proceedings. American Medical Informatics Association; 2006. p.359.
9. Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD, Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American college of physicians. Ann Intern Med 2016;165:125-133.
16. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychaitry Res 1989;28:193-213.
17. Morin CM, Vallieres A, Ivers H. Dysfunctional beliefs and attitudes about sleep (DBAS): validation of a brief version (DBAS-16). Sleep 2007;30:1547-1554.
19. Glenville M, Broughton R. Reliability of the Stanford Sleepiness Scale compared to short duration performance tests and the Wilkinson Auditory Vigilance Task. Adv Biosci 1978;21:235-244.
21. Ong TH, Raudha S, Fook-Chong S, Lew N, Hsu AA. Simplifying STOP-BANG: use of a simple questionnaire to screen for OSA in an Asian population. Sleep Breath 2010;14:371-376.
22. Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med 1999;131:485-491.
23. Horne JA, Ostberg O. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol 1976;4:97-110.
24. Spoormaker VI, Verbeek I, van den Bout J, Klip EC. Initial validation of the SLEEP-50 questionnaire. Behav Sleep Med 2005;3:227-246.
25. Morgenthaler T, Kramer M, Alessi C, Friedman L, Boehlecke B, Brown T, et al. Practice parameters for the psychological and behavioral treatment of insomnia: an update. An American academy of sleep medicine report. Sleep 2006;29:1415-1419.
26. Riemann D, Perlis ML. The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. Sleep Med Rev 2009;13:205-214.
27. Morin CM. Cognitive-behavioral approaches to the treatment of insomnia. J Clin Psychiatry 2004;65(Suppl 16):33-40.
28. Sadock B, Ruiz P. Kaplan & Sadock’s Synopsis of Psychiatry: Behavioral Sciences. New York: Walters Kluwer; 2015.
29. Billioti de Gage S, Pariente A, Begaud B. Is there really a link between benzodiazepine use and the risk of dementia? Expert Opin Drug Saf 2015;14:733-747.
30. Flurazepam, triazolam, flunitrazepam, and brotizolam. Available at:
www.druginfo.co.kr. Accessed August 10, 2018.
31. French DD, Spehar AM, Campbell RR, Palacios P, Coakley RW, Coblio N, et al. Outpatient Benzodiazepine Prescribing, Adverse Events, and Costs. In: Henriksen K, Battles JB, Marks ES, Lewin DI editors. Advances in Patient Safety: from Research to Implementation (Volume 1: Research Findings). Rockville, MD: Agency for Healthcare Research and Quality; 2005. p.185-198.
32. MacFarlane J, Morin CM, Montplaisir J. Hypnotics in insomnia: the experience of zolpidem. Clin Ther 2014;36:1676-1701.
34. Wong CK, Marshall NS, Grunstein RR, Ho SS, Fois RA, Hibbs DE, et al. Spontaneous adverse event reports associated with zolpidem in the United States 2003-2012. J Clin Sleep Med 2017;13:223-234.
35. FDA requires lower dosing of zolpidem. Med Lett Drugs Ther 2013;55:5.
36. Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;23:2597-2605.
37. Yeung WF, Chung KF, Yung KP, Ng TH. Doxepin for insomnia: a systematic review of randomized placebo-controlled trials. Sleep Med Rev 2015;19:75-83.
38. Jaffer KY, Chang T, Vanle B, Dang J, Steiner AJ, Loera N, et al. Trazodone for insomnia: a systematic review. Innov Clin Neurosci 2017;14:24-34.
39. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS spectr 2009;14:536-546.
41. Yi XY, Ni SF, Ghadami MR, Meng HQ, Chen MY, Kuang L, et al. Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med 2018;45:25-32.
42. Vande Griend JP, Anderson SL. Histamine-1 receptor antagonism for treatment of insomnia. J Am Pharm Assoc 2012;52:e210-e219.
45. Youn S, Han CC, Park B, Lee S, Yi K, Chung S. The effects of the new guidance ‘take your sleeping pills 7 h before your wake-up time’: a pilot study. Sleep Biol Rhythms 2016;14:397-404.
46. Chung S, Youn S, Park B, Lee S, Kim C. The effectiveness of prolongedrelease melatonin in primary insomnia patients with a regular sleepwake cycle. Sleep Med Res 2016;7:16-20.
47. Nam Y, Cho C, Lee Y, Lee H. Development of safety usage guidelines for sedative hypnotics using the Delphi technique. Sleep Med Psychophysiol 2019;26:2.